Welcome to our dedicated page for Exponent news (Ticker: EXPO), a resource for investors and traders seeking the latest updates and insights on Exponent stock.
Exponent Inc reports developments in science and engineering consulting, including financial results, client demand across its two operating segments, and capital-return actions. Its engineering and other scientific work includes failure analysis, dispute-related consulting, user research for consumer electronics, utility risk management, asset integrity, transportation, energy, construction, life sciences, and medical device support.
The company’s environmental and health segment is tied to chemical regulation, food safety, ecological and biological sciences, and environmental consulting. Recurring updates also cover quarterly dividends, share repurchase authorizations, conference calls, executive appointments, board matters, and governance changes.
Exponent, Inc. (Nasdaq: EXPO) reported a solid third quarter for fiscal year 2021, with net revenues increasing by 16% to $116.4 million and net income rising to $24.6 million or $0.46 per diluted share. EBITDA improved to $34 million, representing 31.4% of net revenues. The company anticipates mid-single digit revenue growth for Q4 and a decrease in EBITDA margins between 175 to 225 basis points.
Overall, Exponent remains focused on expanding its multidisciplinary services amid growing demand and aims for profitable growth across various sectors.
Exponent, Inc. (Nasdaq: EXPO) will announce its third-quarter fiscal 2021 financial results on October 28, 2021, after market close. CEO Dr. Catherine Corrigan and CFO Richard Schlenker will lead a conference call at 4:30 p.m. ET to discuss the results. Interested parties can access the call via phone or through the company's Investor Relations webpage, where an archived version will also be available later. The firm specializes in engineering and scientific consulting, leveraging decades of expertise to solve complex problems for clients.
Exponent Inc. (Nasdaq: EXPO) has declared a quarterly cash dividend of $0.20 per share, payable on September 24, 2021, to stockholders of record as of September 10, 2021. This decision reflects the company’s strong balance sheet and business resilience. Exponent aims to continue its quarterly dividend payouts in March, June, September, and December. CEO Dr. Catherine Corrigan highlighted the firm’s commitment to delivering valuable solutions to complex challenges, ensuring long-term shareholder value.
Exponent, Inc. (Nasdaq: EXPO) reported strong Q2 2021 results, with net revenue up 30% to $119.9 million, driven by robust demand post-pandemic. EBITDA margin expanded 630 basis points year-over-year, reaching 32.3% of net revenues. Net income increased to $25.4 million, or $0.48 per diluted share, compared to $16.3 million in Q2 2020. The company maintains a positive outlook for the remainder of the year, expecting low-double digit revenue growth and increased EBITDA margins. Exponent reported $240 million in cash and repurchased $7 million of stock.
Exponent, Inc. (EXPO) will report its Q2 fiscal year 2021 financial results on July 29, 2021, after market close. Dr. Catherine Corrigan, CEO, and Richard Schlenker, CFO, will host a conference call at 4:30 p.m. ET to discuss the results. The call will be accessible via a live and archived webcast on the company's Investor Relations website. A telephonic replay will be available until August 5, 2021. Exponent specializes in engineering and scientific consulting, leveraging over 50 years of experience in solving complex problems across various technical disciplines.
Exponent, Inc. (NASDAQ: EXPO) announced the appointment of John Doyle, Dr.P.H., as Group Vice President, Health Sciences on May 17, 2021. Dr. Doyle will lead the company's Health Sciences team, addressing environmental, occupational, medical, and public health challenges. CEO Dr. Catherine Corrigan highlighted Dr. Doyle's experience in healthcare research and the pharmaceutical sector, aiming to drive growth in life sciences. Dr. Doyle has authored over 200 research articles, primarily in oncology, and holds advanced degrees in Epidemiology from Columbia University.
Exponent, Inc. (Nasdaq:EXPO) announced that CEO Dr. Catherine Corrigan and CFO Richard Schlenker will present at the Berenberg Conference USA 2021 on May 18, 2021, at 11:00 AM PT. Investors can access a live webcast of this presentation on Exponent's investor relations website, with an archived replay available afterward. Exponent is known for its engineering and scientific consulting, leveraging over 50 years of experience to tackle complex challenges across various sectors.
Exponent, Inc. (Nasdaq:EXPO) declared a quarterly cash dividend of $0.20 per share, to be paid on June 25, 2021, to stockholders of record as of June 11, 2021. The company has consistently increased dividends, marking the eighth consecutive year of growth, reflecting its strong balance sheet and commitment to long-term shareholder value. Exponent plans to continue quarterly dividends in March, June, September, and December, contingent upon Board approval.
Exponent, Inc. (Nasdaq:EXPO) reported a 10% increase in net revenues for Q1 FY2021, totaling $116.5 million. EBITDA rose to $31.8 million, reflecting a margin improvement of 400 basis points year-over-year. Net income grew to $30.8 million or $0.58 per diluted share. The engineering segment contributed 81% of revenues with an 11% growth, while the environmental segment saw a 7% increase. Exponent anticipates continued growth with Q2 revenue growth projected in the low twenties and full-year guidance in the high-single to low-double digits.
Exponent, Inc. (Nasdaq: EXPO) announced it will report its first quarter fiscal year 2021 financial results on April 29, 2021, after market close. The conference call hosted by CEO Dr. Catherine Corrigan and CFO Richard Schlenker will begin at 4:30 p.m. ET. Shareholders can access the call live or via archived webcast on the company's Investor Relations page. A telephonic replay will also be available until May 6, 2021.